Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases.

Chin LT, Chu C, Chen HM, Wang DW, Liao SK.

Chang Gung Med J. 2008 Jan-Feb;31(1):1-15. Review.

2.

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I.

An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. Review. Spanish.

3.

Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.

Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester GR, Jorch G, Nadler SG, Bröker B, Hebel K, Brunner-Weinzierl MC.

J Immunol. 2009 May 1;182(9):5342-51. doi: 10.4049/jimmunol.0801624.

5.
6.

Identification of protein-protein interfaces implicated in CD80-CD28 costimulatory signaling.

Sørensen P, Kussmann M, Rosén A, Bennett KL, Thrige Dda G, Uvebrant K, Walse B, Roepstorff P, Björk P.

J Immunol. 2004 Jun 1;172(11):6803-9.

7.

Targeting costimulatory pathways for tumor immunotherapy.

Ward RC, Kaufman HL.

Int Rev Immunol. 2007 May-Aug;26(3-4):161-96. Review.

PMID:
17558743
8.

The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology.

Sansom DM, Walker LS.

Immunol Rev. 2006 Aug;212:131-48. Review.

PMID:
16903911
9.

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation.

Wing K, Yamaguchi T, Sakaguchi S.

Trends Immunol. 2011 Sep;32(9):428-33. doi: 10.1016/j.it.2011.06.002. Epub 2011 Jun 30. Review.

PMID:
21723783
10.

Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.

Saverino D, Brizzolara R, Simone R, Chiappori A, Milintenda-Floriani F, Pesce G, Bagnasco M.

Clin Immunol. 2007 May;123(2):190-8. Epub 2007 Feb 23.

PMID:
17321799
11.

Costimulation: critical pathways in the immunologic regulation of asthma.

Bellou A, Finn PW.

Curr Allergy Asthma Rep. 2005 Mar;5(2):149-54. Review.

PMID:
15683616
12.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925
13.

CTLA-4 control over Foxp3+ regulatory T cell function.

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S.

Science. 2008 Oct 10;322(5899):271-5. doi: 10.1126/science.1160062.

14.

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.

Wolchok JD, Saenger Y.

Oncologist. 2008;13 Suppl 4:2-9. doi: 10.1634/theoncologist.13-S4-2. Review.

15.

CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice.

Kolar P, Knieke K, Hegel JK, Quandt D, Burmester GR, Hoff H, Brunner-Weinzierl MC.

Arthritis Rheum. 2009 Jan;60(1):123-32. doi: 10.1002/art.24181.

16.

CD80 binding polyproline helical peptide inhibits T cell activation.

Srinivasan M, Lu D, Eri R, Brand DD, Haque A, Blum JS.

J Biol Chem. 2005 Mar 18;280(11):10149-55. Epub 2004 Dec 14.

17.

CTLA-4 (CD152) and its involvement in autoimmune disease.

Holmberg D, Cilio CM, Lundholm M, Motta V.

Autoimmunity. 2005 May;38(3):225-33. Review.

PMID:
16126511
18.

Altering immune tolerance therapeutically: the power of negative thinking.

Prud'homme GJ.

J Leukoc Biol. 2004 Apr;75(4):586-99. Epub 2003 Dec 4. Review.

19.

Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.

Darlington PJ, Kirchhof MG, Criado G, Sondhi J, Madrenas J.

J Immunol. 2005 Jul 15;175(2):996-1004.

20.

CTLA-4: negative regulator of the immune response and a target for cancer therapy.

Keilholz U.

J Immunother. 2008 Jun;31(5):431-9. doi: 10.1097/CJI.0b013e318174a4fe. Review.

PMID:
18463542
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk